HIV infection

LG Bekker, C Beyrer, N Mgodi, SR Lewin… - Nature Reviews …, 2023 - nature.com
The AIDS epidemic has been a global public health issue for more than 40 years and has
resulted in~ 40 million deaths. AIDS is caused by the retrovirus, HIV-1, which is transmitted …

HIV and antiretroviral therapy-related fat alterations

JR Koethe, C Lagathu, JE Lake, P Domingo… - Nature reviews Disease …, 2020 - nature.com
Early in the HIV epidemic, lipodystrophy, characterized by subcutaneous fat loss
(lipoatrophy), with or without central fat accumulation (lipohypertrophy), was recognized as a …

Cabotegravir for HIV prevention in cisgender men and transgender women

RJ Landovitz, D Donnell, ME Clement… - … England Journal of …, 2021 - Mass Medical Soc
Background Safe and effective long-acting injectable agents for preexposure prophylaxis
(PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options …

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a …

KH Mayer, JM Molina, MA Thompson, PL Anderson… - The Lancet, 2020 - thelancet.com
Background Tenofovir alafenamide shows high antiviral efficacy and improved renal and
bone safety compared with tenofovir disoproxil fumarate when used for HIV treatment. Here …

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial …

WDF Venter, S Sokhela, B Simmons, M Moorhouse… - The lancet HIV, 2020 - thelancet.com
Background ADVANCE compared the efficacy and safety of two antiretroviral first-line
combinations (dolutegravir combined with emtricitabine and either tenofovir disoproxil …

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA Panel

MS Saag, RT Gandhi, JF Hoy, RJ Landovitz… - Jama, 2020 - jamanetwork.com
Importance Data on the use of antiretroviral drugs, including new drugs and formulations, for
the treatment and prevention of HIV infection continue to guide optimal practices. Objective …

Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3-or 4-drug regimen for maintaining virologic suppression in adults …

JM Llibre, C Brites, CY Cheng, O Osiyemi… - Clinical Infectious …, 2023 - academic.oup.com
Background In TANGO, switching to dolutegravir/lamivudine (DTG/3TC) demonstrated long-
term noninferior efficacy vs continuing tenofovir alafenamide–based regimens in treatment …

Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors …

K Bourgi, CA Jenkins, PF Rebeiro… - Journal of the …, 2020 - Wiley Online Library
Introduction Weight gain following antiretroviral therapy (ART) initiation is common,
potentially predisposing some persons with HIV (PWH) to cardio‐metabolic disease. We …

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

C Orkin, S Oka, P Philibert, C Brinson, A Bassa… - The lancet HIV, 2021 - thelancet.com
Background There is a need for more convenient, less frequent treatment to help address
challenges associated with daily oral HIV treatment in people living with HIV, including …